Treatment of dural arteriovenous fistula using ethylene vinyl alcohol (onyx) arterial embolization as the primary modality: short-term results

J Neurosurg. 2007 Dec;107(6):1120-5. doi: 10.3171/JNS-07/12/1120.

Abstract

Object: A dural arteriovenous fistula (DAVF) typically involves meningeal feeding arteries and can cause clinical symptoms ranging from tinnitus to rupture of draining cortical or parenchymal veins. Surgical treatment may be technically demanding. Ethylene vinyl alcohol (Onyx, ev3 Neurovascular) has several properties that make it potentially useful as a primary treatment agent for DAVF. Onyx is expected to be a permanent embolic agent. It should have a decreased risk of catheter retention when compared with other permanent embolic materials.

Methods: The authors report a series of six patients with symptomatic DAVF who were treated initially with transarterial Onyx embolization and other endovascular techniques.

Results: Five patients had complete occlusion of their DAVF noted on the follow-up angiogram obtained between 2 and 4 months. One patient had residual filling via a small arterial branch that was stable on follow-up angiography. None of the patients had worsening of neurological function. One case was complicated by a retained catheter fragment.

Conclusions: Transarterial Onyx embolization and other endovascular methods can angiographically obliterate DAVF. In some cases, embolization allowed occlusion of multiple arterial feeding arteries from a single arterial injection. Technically, the embolization was optimized when a microcatheter position immediately adjacent to the point(s) of fistulization was achieved.

Publication types

  • Case Reports

MeSH terms

  • Adult
  • Aged
  • Catheterization / adverse effects
  • Central Nervous System Vascular Malformations / diagnostic imaging
  • Central Nervous System Vascular Malformations / therapy*
  • Cerebral Angiography
  • Dura Mater / blood supply*
  • Embolization, Therapeutic / adverse effects
  • Embolization, Therapeutic / methods*
  • Humans
  • Male
  • Middle Aged
  • Polyvinyl Chloride / therapeutic use*
  • Time Factors
  • Treatment Outcome

Substances

  • Polyvinyl Chloride